β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats

β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats

Abstract Background Non-alcoholic steatohepatitis (NASH) is a chronic disease characterized by inflammation, steatosis, and liver fibrosis. The liver is particularly affected by alterations in lipid metabolism. Our aim was to evaluate the effect of β-hydroxyphosphocarnitine (β-HPC) on NASH induced i...

Full description

Bibliographic Details
Main Authors: Janet Sánchez-Quevedo, Emmanuel Ocampo-Rodríguez, Elizabeth Alvarez-Ayala, Anahí Rodríguez-López, Miguel Angel Duarte-Vázquez, Jorge Luis Rosado, Lourdes Rodríguez-Fragoso
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Pharmacology and Toxicology
Subjects:
Non-alcoholic steatohepatitis
Fibrosis
Steatosis
Inflammation
β-hydroxyphosphocarnitine
Online Access:https://doi.org/10.1186/s40360-022-00613-2

Internet

https://doi.org/10.1186/s40360-022-00613-2

Similar Items